NCT05005338View on ClinicalTrials.gov

A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

July 28, 2021

Primary Completion Date

September 23, 2021

Study Completion Date

September 23, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

BIIB122 (DNL151)

Oral doses

DRUG

[14C] BIIB122 ([14C] DNL151)

Intravenous doses

Trial Locations (1)

21201

Pharmaron CPC, Baltimore

Sponsors

Lead Sponsor

Biogen

Collaborators (1)

Denali Therapeutics Inc.
All Listed Sponsors
collaborator

Denali Therapeutics Inc.

INDUSTRY

lead

Biogen

INDUSTRY

NCT05005338 - A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy Subjects | Biotech Hunter | Biotech Hunter